1.The new study aimed to see if addition of the drug cetuximab, also known as Erbitux, would help patients even more.
最新的研究看出如果加用西妥昔单抗（又名爱比妥）可以明显增加这种手术切除的优势。
2.Objective As EGFR inhibitor, Cetuximab has been widely used in several solid tumors, and has perfect therapeutic effect and security.
目的作为EGFR抑制剂，西妥昔单抗在多种实体瘤中应用日益广泛，显示出良好的疗效和安全性。
3.The pharmacologic actions of cetuximab and its clinical evaluation are reviewed in this paper.
本文综述了西妥昔单抗的药理作用及临床评价。
4.Biopsies and plasma samples were taken before treatment, after cetuximab but before CRT, and at the time of surgery.
治疗前先行活组织检查和血浆样本的采集，西妥昔单抗应用之前，CRT之前，即手术的时机。
5.The use of cetuximab for colorectal cancer was highest in France and the United States and lowest in Finland.
法国及美国应用西妥昔单抗治疗直肠结肠癌最多，而芬兰最低。
6.The use of bevacizumab (as well as cetuximab) for maintenance remains unproven, however.
贝伐单抗（以及西妥昔单抗）对维持治疗仍无提高。
7.In these patients, severe hypomagnesaemia recurs rarely within 2 months from the start of cetuximab rechallenge.
这些病人中，西妥昔单抗二次给药两个月内复发严重低镁血症的极少。
8.We previously showed that KRAS mutations were associated with resistance to cetuximab in 30 CRC patients.
我们之前研究显示：KRAS突变与30个CRC患者对西妥昔单抗耐药有关。
9.EMEA, the European Medicines Agency, has already restricted use of cetuximab and panitumumab to such patients.
欧洲药品局EMEA已经限制西妥昔单抗和帕尼单抗在这些患者使用。
10.based on favourable time-to-progression (TTP) and response-rate outcomes from the Bowel Oncology with Cetuximab Antibody (BOND) study.
基于有利的，从西妥昔单抗治疗肠肿瘤的研究得出，时间-进程（TTP）的和应答率的结果。